Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer.

ABSTRACT: In recent years, there have been significant advances in the treatment of breast cancer resulting in remarkably high survival rates. However, treatment options for metastatic triple negative breast cancer (TNBC) are quite limited due to a lack of identifiable, unique markers. Using a phage display-based whole cell biopanning procedure, we developed two human antibodies that bind to tumor cells with a metastatic TNBC phenotype. Our studies further identified domain 1 of HSPG2 (perlecan) protein as the cognate cell surface antigen bound by the antibody. Immunohistochemistry studies utilizing patient tissue samples revealed significant cell surface expression of HSPG2 in both primary tumors and metastatic lesions. Further, higher HSPG2 expression correlated with poor survival in TNBC. The aff

SUBMITTER: Kalscheuer S 

PROVIDER: S-EPMC6713791 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature